Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma

Ross J Mason¹, Lori Wood², Anil Kapoor³, Naveen Basappa⁴, George Bjarnason⁵, Stephen A Boorjian⁶, Rodney H Breau⁷, Ilias Cagiannos⁷, Michael A S Jewett⁸, Pierre I Karakiewicz⁹, Wassim Kassouf¹⁰, Christian Kollmannsberger¹¹, Aly-Khan A Lalani¹², Jean-Baptiste Lattouf⁹, Luke T Lavallée⁷, Stephen Pautler¹³, Nicholas Power¹³, Patrick Richard¹⁴, Alan So¹⁵, Simon Tanguay¹⁰, Ricardo A Rendon¹

Affiliations

¹ Department of Urology, Dalhousie University, Halifax, NS, Canada.
² Division of Medical Oncology, Dalhousie University, Halifax, NS, Canada.
³ Division of Urology, McMaster University, Hamilton, ON, Canada.
⁴ Division of Medical Oncology, University of Alberta, Edmonton, AB, Canada.
⁵ Division of Medical Oncology, University of Toronto, Toronto, ON, Canada.
⁶ Department of Urology, Mayo Clinic, Rochester, MN, United States.
⁷ Division of Urology, University of Ottawa, Ottawa, ON, Canada.
⁸ Division of Urology, University of Toronto, Toronto, ON, Canada.
⁹ Département de Chirurgie (Urologie), Université de Montréal, Montreal, QC, Canada.
¹⁰ Division of Urology, McGill University, Montreal, QC, Canada.
¹¹ Division of Medical Oncology, University of British Colombia, Vancouver, BC, Canada.
¹² Department of Oncology, McMaster University, Hamilton, ON, Canada.
¹³ Division of Urology, Western University, London, ON, Canada.
¹⁴ Division of Urology, Université de Sherbrooke, Sherbrooke, QC, Canada.
¹⁵ Department of Urologic Sciences, University of British Colombia, Vancouver, BC, Canada.

PMID: 31199235
PMCID: PMC6570591
DOI: 10.5489/cuaj.5786

Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma

Ross J Mason et al. Can Urol Assoc J. 2019 Jun.

. 2019 Jun;13(6):166-174.

doi: 10.5489/cuaj.5786.

Authors

Affiliations

¹ Department of Urology, Dalhousie University, Halifax, NS, Canada.
² Division of Medical Oncology, Dalhousie University, Halifax, NS, Canada.
³ Division of Urology, McMaster University, Hamilton, ON, Canada.
⁴ Division of Medical Oncology, University of Alberta, Edmonton, AB, Canada.
⁵ Division of Medical Oncology, University of Toronto, Toronto, ON, Canada.
⁶ Department of Urology, Mayo Clinic, Rochester, MN, United States.
⁷ Division of Urology, University of Ottawa, Ottawa, ON, Canada.
⁸ Division of Urology, University of Toronto, Toronto, ON, Canada.
⁹ Département de Chirurgie (Urologie), Université de Montréal, Montreal, QC, Canada.
¹⁰ Division of Urology, McGill University, Montreal, QC, Canada.
¹¹ Division of Medical Oncology, University of British Colombia, Vancouver, BC, Canada.
¹² Department of Oncology, McMaster University, Hamilton, ON, Canada.
¹³ Division of Urology, Western University, London, ON, Canada.
¹⁴ Division of Urology, Université de Sherbrooke, Sherbrooke, QC, Canada.
¹⁵ Department of Urologic Sciences, University of British Colombia, Vancouver, BC, Canada.

PMID: 31199235
PMCID: PMC6570591
DOI: 10.5489/cuaj.5786

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Wood has been an advisory board member (with no compensation) for Astellas, Pfizer, and Novartis; and has participated in clinical trials supported by Aragon, AstraZeneca, BMS, Exelixis, Merck, Pfizer, and Roche. Dr. Kapoor has been an advisory board member for BMS, Eisai, Ipsen, Merck, Novartis, Pfizer, and Roche; a speakers bureau member for Eisai, Ipsen, Novartis, and Roche; and has received honoraria from BMS, Eisai, Ipsen, Merck, Novartis, Pfizer, and Roche. Dr. Basappa has been an advisory board member for Astellas, AstraZeneca, BI, BMS, Janssen, Novartis, and Pfizer; and has received honoraria from Astellas, BMS, Janssen, Novartis, and Pfizer. Dr. Cagiannos has been an advisory board member for Abbvie and Ferring; and has received honoraria from Abbvie, Acerus, and Ferring. Dr. Jewett has been an advisory board member for Pfizer and Theralase Tech; has received honoraria from Olympus, Pfizer, and Theralase Tech; and holds investments in Theralase Tech. Dr. Kassouf has received honoraria from Astellas, AstraZeneca, Janssen, Merck, and Roche. Dr. Kollmannsberger has been an advisory board member for Astellas, BMS, Novartis, Pfizer, and Sanofi; has received honoraria from BMS, Novartis, and Pfizer; and has participated in clinical trials supported by Astellas, AstraZeneca, BMS, Janssen, Merck, Novartis, Pfizer, and Sanofi. Dr. Lavallée has been an advisory board member for Ferring and Sanofi; and received a grant from Sanofi. Dr. Richard has been an advisory board member for Sanofi; and has received compenstaion from Abbvie, Astellas, and Janssen. Dr. So has been an advisory board member for Abbvie, Amgen, Astellas, Bayer, Ferring, Janssen, and Tersera; and has participated in clinical trials supported by Astellas, Ferring, and Janssen. Dr. Tanguay has been an advisory board member for Pfizer; and has received a travel grant from Sanofi. Dr. Rendon has been both an advisory board member and a speakers bureau member for and has received grants/honoraria from Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, Ferring, Jansen and Sanofi Aventis. The remaining authors report no personal or financial conflicts related to this work.

Cited by

Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.
Hotte SJ, Kapoor A, Basappa NS, Bjarnason G, Canil C, Conter HJ, Czaykowski P, Graham J, Gray S, Heng DYC, Karakiewicz PI, Kollmannsberger C, Lalani AA, North SA, Patenaude F, Soulières D, Violette P, Winquist E, Wood LA, Dudani S, Maloni R, Reaume MN; Kidney Cancer Research Network of Canada. Hotte SJ, et al. Can Urol Assoc J. 2019 Oct;13(10):343-354. doi: 10.5489/cuaj.6256. Can Urol Assoc J. 2019. PMID: 31603413 Free PMC article. No abstract available.
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma.
Ingels A, Campi R, Capitanio U, Amparore D, Bertolo R, Carbonara U, Erdem S, Kara Ö, Klatte T, Kriegmair MC, Marchioni M, Mir MC, Ouzaïd I, Pavan N, Pecoraro A, Roussel E, de la Taille A. Ingels A, et al. Nat Rev Urol. 2022 Jul;19(7):391-418. doi: 10.1038/s41585-022-00592-3. Epub 2022 May 11. Nat Rev Urol. 2022. PMID: 35546184 Review.
Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma.
Zheng W, Zhu W, Yu S, Li K, Ding Y, Wu Q, Tang Q, Zhao Q, Lu C, Guo C. Zheng W, et al. BMC Cancer. 2020 Nov 4;20(1):1066. doi: 10.1186/s12885-020-07586-7. BMC Cancer. 2020. PMID: 33148204 Free PMC article.
DCS, a novel classifier system based on disulfidptosis reveals tumor microenvironment heterogeneity and guides frontline therapy for clear cell renal carcinoma.
Jiang A, Liu W, Liu Y, Hu J, Zhu B, Fang Y, Zhao X, Qu L, Lu J, Liu B, Qi L, Cai C, Luo P, Wang L. Jiang A, et al. J Natl Cancer Cent. 2024 Jun 17;4(3):263-279. doi: 10.1016/j.jncc.2024.06.003. eCollection 2024 Sep. J Natl Cancer Cent. 2024. PMID: 39281723 Free PMC article.
2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma.
Graham J, Ahmad AE, Basappa NS, Bernhard JC, Bhindi B, Bossé D, Breau RH, Canil CM, Castonguay V, Finelli A, Heng DYC, Inman BA, Kollmannsberger C, Lalani AA, Lavallée LT, Msaouel P, Prendeville S, Soleimani M, Tanguay S, Wood L, Richard PO. Graham J, et al. Can Urol Assoc J. 2024 Nov;18(11):E371-E386. doi: 10.5489/cuaj.9041. Can Urol Assoc J. 2024. PMID: 39500366 Free PMC article. No abstract available.

See all "Cited by" articles

References

1. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomized trial. Lancet. 2001;358:966–70. doi: 10.1016/S0140-6736(01)06103-7. - DOI - PubMed
1. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–9. doi: 10.1056/NEJMoa003013. - DOI - PubMed
1. Mejean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379:417–27. doi: 10.1056/NEJMoa1803675. - DOI - PubMed
1. Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The SURTIME randomized clinical trial. JAMA Oncol. 2019 doi: 10.1001/jamaoncol.2018.5543. [Epub ahead of print]. - DOI - PMC - PubMed
1. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab vs. sunitinib in advanced renal cell carcinoma. N Engl J Med. 2018;378:1277–90. doi: 10.1056/NEJMoa1712126. - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma

Affiliations

Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Conflict of interest statement

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources